newsfilter
← Latest News
Business Wire·

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

RHHBY
  • Enicepatide 24 mg achieved a mean HbA1c reduction of 2.65% at 48 weeks, with a 4.13% reduction observed in patients having baseline HbA1c >8.5%
  • 90% of patients on the 24 mg dose reached the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (<5.7%)
  • Patients on the 24 mg dose experienced a mean weight loss of 15.5% at 48 weeks without a weight loss plateau
  • The drug demonstrated a safety profile consistent with incretin therapies, featuring low discontinuation rates (2.0%) due to adverse events
  • Genentech plans to initiate Phase III glycemic-control programs & cardiovascular outcomes trials in the first half of 2027
  • The Phase II study CT-388-104 evaluated 447 adults with T2D & overweight/obesity using a once-weekly dual GLP-1/GIP receptor agonist